Table 4.
Results of meta-regression
| Covariates | The exponent of b | Standard error | t | P>|t| | 95% CI | R-squared | |
|---|---|---|---|---|---|---|---|
| Country | 0.9739739 | 0.1127419 | −0.23 | 0.826 | 0.457975 | 1.271961 | −57.20% |
| Study design | 0.764022 | 0.1834384 | −1.12 | 0.295 | 0.4391912 | 1.329101 | −29.22% |
| CHGA levels measurements | 0.9011292 | 0.1091306 | −0.86 | 0.415 | 0.6815581 | 1.191437 | −27.62% |
| Clinical tumor stage | 0.9203951 | 0.2434193 | −0.31 | 0.762 | 0.5001601 | 1.693712 | −49.17% |
Notes: Country (1=Italy, 2=USA, 3=UK, 4=Germany); study design (1=retrospective cohort, 2=prospective cohort); CHGA levels measurements (1=plasma, 2=tissue, 3=serum); and clinical tumor stage (1=CRPC, 2=prostate cancer).
Abbreviations: CHGA, chromogranin-A protein; CRPC, castration-resistant prostate cancer.